tiprankstipranks
Keymed Biosciences, Inc. (HK:2162)
:2162
Hong Kong Market
2162
Keymed Biosciences, Inc.
RESEARCH TOOLSreports
Want to see HK:2162 full AI Analyst Report?

Keymed Biosciences, Inc. (2162) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

2162 Analyst Ratings

Strong Buy
4Ratings
Strong Buy
4 Buy
0 Hold
0 Sell
Based on 4 analysts giving stock ratings to
Keymed
Biosciences, Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

2162 Stock 12 Month Forecast

Average Price Target

HK$91.23
▲(45.27% Upside)
Based on 4 Wall Street analysts offering 12 month price targets for Keymed Biosciences, Inc. in the last 3 months. The average price target is HK$91.23 with a high forecast of HK$97.00 and a low forecast of HK$87.31. The average price target represents a 45.27% change from the last price of HK$62.80.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"40":"HK$40","69":"HK$69","98":"HK$98","54.5":"HK$54.5","83.5":"HK$83.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":97,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$97.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":91.2275,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$91.23</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":87.31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$87.31</span>\n  </div></div>","useHTML":true}}],"tickPositions":[40,54.5,69,83.5,98],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,60.65,63.44615384615385,66.24230769230769,69.03846153846153,71.83461538461539,74.63076923076923,77.42692307692307,80.22307692307692,83.01923076923077,85.81538461538462,88.61153846153846,91.40769230769232,94.20384615384616,{"y":97,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,60.65,63.00211538461539,65.35423076923077,67.70634615384616,70.05846153846154,72.41057692307692,74.7626923076923,77.11480769230769,79.46692307692308,81.81903846153847,84.17115384615386,86.52326923076924,88.87538461538462,{"y":91.2275,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,60.65,62.70076923076923,64.75153846153846,66.80230769230769,68.85307692307693,70.90384615384616,72.95461538461538,75.00538461538461,77.05615384615385,79.10692307692308,81.15769230769232,83.20846153846153,85.25923076923077,{"y":87.31,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":41.75,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.2,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":61.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.25,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.25,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.45,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.45,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.1,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.1,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.55,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.65,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetHK$97.00Average Price TargetHK$91.23Lowest Price TargetHK$87.31
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on HK:2162
Unknown Analyst
Morgan Stanley
Not Ranked
Morgan Stanley
HK$97
Buy
54.46%
Upside
Reiterated
05/28/26
Morgan Stanley Sticks to Their Buy Rating for Keymed Biosciences, Inc. (2162)
Shenwan Hongyuan Analyst forecast on HK:2162
Unknown Analyst
Shenwan Hongyuan
Not Ranked
Shenwan Hongyuan
HK$89.47
Buy
42.47%
Upside
Reiterated
05/27/26
Shenwan Hongyuan Keeps Their Buy Rating on Keymed Biosciences, Inc. (2162)
KeyBanc Analyst forecast on HK:2162
Unknown Analyst
KeyBanc
Not Ranked
KeyBanc
HK$87.31
Buy
39.03%
Upside
Reiterated
04/03/26
KeyBanc Sticks to Their Buy Rating for Keymed Biosciences, Inc. (2162)
Huatai Securities Analyst forecast on HK:2162
Unknown Analyst
Huatai Securities
Not Ranked
Huatai Securities
HK$91.08→HK$91.13
Buy
45.11%
Upside
Reiterated
03/29/26
Huatai Securities Remains a Buy on Keymed Biosciences, Inc. (2162)
CLSA Analyst forecast on HK:2162
Unknown Analyst
CLSA
Not Ranked
CLSA
HK$78
Buy
24.20%
Upside
Reiterated
03/24/26
Keymed Biosciences, Inc. (2162) Receives a Buy from CLSA
Sinolink Securities Analyst forecast on HK:2162
Unknown Analyst
Sinolink Securities
Not Ranked
Sinolink Securities
HK$83.29
Buy
32.63%
Upside
Reiterated
12/25/25
Keymed Biosciences, Inc. (2162) Receives a Buy from Sinolink Securities
SPDB Analyst forecast on HK:2162
Unknown Analyst
SPDB
Not Ranked
SPDB
HK$77
Buy
22.61%
Upside
Reiterated
08/29/25
Citi Analyst forecast on HK:2162
Unknown Analyst
Citi
Not Ranked
Citi
HK$85
Buy
35.35%
Upside
Reiterated
08/28/25
BOCOM International Holdings Company Analyst forecast on HK:2162
Unknown Analyst
BOCOM International Holdings Company
Not Ranked
BOCOM International Holdings Company
HK$78
Buy
24.20%
Upside
Reiterated
08/28/25
CICC Analyst forecast on HK:2162
Unknown Analyst
CICC
Not Ranked
CICC
HK$85
Buy
35.35%
Upside
Reiterated
08/27/25
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on HK:2162
Unknown Analyst
Morgan Stanley
Not Ranked
Morgan Stanley
HK$97
Buy
54.46%
Upside
Reiterated
05/28/26
Morgan Stanley Sticks to Their Buy Rating for Keymed Biosciences, Inc. (2162)
Shenwan Hongyuan Analyst forecast on HK:2162
Unknown Analyst
Shenwan Hongyuan
Not Ranked
Shenwan Hongyuan
HK$89.47
Buy
42.47%
Upside
Reiterated
05/27/26
Shenwan Hongyuan Keeps Their Buy Rating on Keymed Biosciences, Inc. (2162)
KeyBanc Analyst forecast on HK:2162
Unknown Analyst
KeyBanc
Not Ranked
KeyBanc
HK$87.31
Buy
39.03%
Upside
Reiterated
04/03/26
KeyBanc Sticks to Their Buy Rating for Keymed Biosciences, Inc. (2162)
Huatai Securities Analyst forecast on HK:2162
Unknown Analyst
Huatai Securities
Not Ranked
Huatai Securities
HK$91.08→HK$91.13
Buy
45.11%
Upside
Reiterated
03/29/26
Huatai Securities Remains a Buy on Keymed Biosciences, Inc. (2162)
CLSA Analyst forecast on HK:2162
Unknown Analyst
CLSA
Not Ranked
CLSA
HK$78
Buy
24.20%
Upside
Reiterated
03/24/26
Keymed Biosciences, Inc. (2162) Receives a Buy from CLSA
Sinolink Securities Analyst forecast on HK:2162
Unknown Analyst
Sinolink Securities
Not Ranked
Sinolink Securities
HK$83.29
Buy
32.63%
Upside
Reiterated
12/25/25
Keymed Biosciences, Inc. (2162) Receives a Buy from Sinolink Securities
SPDB Analyst forecast on HK:2162
Unknown Analyst
SPDB
Not Ranked
SPDB
HK$77
Buy
22.61%
Upside
Reiterated
08/29/25
Citi Analyst forecast on HK:2162
Unknown Analyst
Citi
Not Ranked
Citi
HK$85
Buy
35.35%
Upside
Reiterated
08/28/25
BOCOM International Holdings Company Analyst forecast on HK:2162
Unknown Analyst
BOCOM International Holdings Company
Not Ranked
BOCOM International Holdings Company
HK$78
Buy
24.20%
Upside
Reiterated
08/28/25
CICC Analyst forecast on HK:2162
Unknown Analyst
CICC
Not Ranked
CICC
HK$85
Buy
35.35%
Upside
Reiterated
08/27/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Keymed Biosciences, Inc.

3 Months
Jack LinMorgan Stanley
Success Rate
0/1 ratings generated profit
0%
Average Return
-25.20%
Copying Jack Lin's trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -25.20% per trade.
1 Year
Jack LinMorgan Stanley
Success Rate
0/1 ratings generated profit
0%
Average Return
-17.20%
Copying Jack Lin's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -17.20% per trade.
2 Years
Jack LinMorgan Stanley
Success Rate
0/1 ratings generated profit
0%
Average Return
-17.20%
Copying Jack Lin's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -17.20% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

2162 Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
1
2
2
4
2
Buy
0
1
2
2
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
1
3
4
6
3
In the current month, 2162 has received 3 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 2162 average Analyst price target in the past 3 months is 91.23.
Each month's total comprises the sum of three months' worth of ratings.

2162 Financial Forecast

2162 Earnings Forecast

Next quarter’s earnings estimate for 2162 is HK$6.58 with a range of HK$6.58 to HK$6.58. The previous quarter’s EPS was -HK$1.84. 2162 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 2162 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 2162 is HK$6.58 with a range of HK$6.58 to HK$6.58. The previous quarter’s EPS was -HK$1.84. 2162 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 2162 has Performed in-line its overall industry.

2162 Sales Forecast

Next quarter’s sales forecast for 2162 is HK$950.19M with a range of HK$950.19M to HK$950.19M. The previous quarter’s sales results were HK$238.18M. 2162 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 2162 has Performed in-line its overall industry.
Next quarter’s sales forecast for 2162 is HK$950.19M with a range of HK$950.19M to HK$950.19M. The previous quarter’s sales results were HK$238.18M. 2162 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 2162 has Performed in-line its overall industry.

2162 Stock Forecast FAQ

What is HK:2162’s average 12-month price target, according to analysts?
Based on analyst ratings, Keymed Biosciences, Inc.’s 12-month average price target is 91.23.
    What is HK:2162’s upside potential, based on the analysts’ average price target?
    Keymed Biosciences, Inc. has 45.27% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Keymed Biosciences, Inc. a Buy, Sell or Hold?
          Keymed Biosciences, Inc. has a consensus rating of Strong Buy, which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Keymed Biosciences, Inc.’s share price target?
            The average share price target for Keymed Biosciences, Inc. is 91.23. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is HK$97.00 ,and the lowest forecast is HK$87.31. The average share price target represents 45.27% Increase from the current price of HK$62.8.
              What do analysts say about Keymed Biosciences, Inc.?
              Keymed Biosciences, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
                How can I buy shares of Keymed Biosciences, Inc.?
                To buy shares of HK:2162, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.